Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vitreoretinopathy Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Isotretinoin
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced May 22, 2026, 5:44 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
Interventions
Intravitreal aflibercept injection, Sham control
Drug · Other
Lead sponsor
M. Ali Khan, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Retinal Detachment, Proliferative Vitreoretinopathy, Retinoschisis
Interventions
Triamcinolone, Bupivicaine Hydrochloride
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
Drug · Other
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced May 22, 2026, 5:44 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Retinal Detachment, Vitrectomy, Proliferative Vitreoretinopathy, Diabetic Retinopathy
Interventions
1000 centistoke silicone oil, 5000 centistoke silicone oil
Procedure
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced May 22, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Osteoporosis Pseudoglioma
Interventions
Lithium
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
4 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced May 22, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Retinal Detachment, Vitreoretinopathy Proliferative
Interventions
Bevacizumab
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced May 22, 2026, 5:44 AM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Osteoporosis Pseudoglioma Syndrome
Interventions
Human recombinant growth hormone
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced May 22, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced May 22, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Pred Forte
Drug
Lead sponsor
Lejla Vajzovic, MD, FASRS
Other
Eligibility
3 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 5:44 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Methotrexate
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced May 22, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
Interventions
Methotrexate Injection, Methotrexate Infusion, Sham Injection
Drug
Lead sponsor
Cincinnati Eye Institute, Southwest Ohio
Other
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 5:44 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced May 22, 2026, 5:44 AM EDT